Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation

RATIONALE: A high incidence of GLA IVS4+919 G>A mutation in patients with Fabry disease of the later-onset cardiac phenotype, has been reported in Taiwan. However, suitable biomarkers or potential therapeutic surrogates for Fabry cardiomyopathy (FC) in such patients under enzyme replacement treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chien, Yueh, Chien, Chian-Shiu, Chiang, Huai-Chih, Huang, Wei-Lin, Chou, Shih-Jie, Chang, Wei-Chao, Chang, Yuh-Lih, Leu, Hsin-Bang, Chen, Kuan-Hsuan, Wang, Kang-Ling, Lai, Ying-Hsiu, Liu, Yung-Yang, Lu, Kai-Hsi, Li, Hsin-Yang, Sung, Yen-Jen, Jong, Yuh-Jyh, Chen, Yann-Jang, Chen, Chung-Hsuan, Yu, Wen-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349979/
https://www.ncbi.nlm.nih.gov/pubmed/27888626
http://dx.doi.org/10.18632/oncotarget.13552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349979/
https://www.ncbi.nlm.nih.gov/pubmed/27888626
http://dx.doi.org/10.18632/oncotarget.13552

Ejemplares similares